In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed their planned investments in the country, each by at least $1 billion.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed their planned investments in the country, each by at least $1 billion.